Evaluation of FVIII pharmacokinetic profiles in Korean hemophilia A patients assessed with myPKFiT: a retrospective chart review
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Evaluation of FVIII pharmacokinetic profiles in Korean hemophilia A patients assessed with myPKFiT: a retrospective chart review ; volume:59 ; number:1 ; day:28 ; month:8 ; year:2024 ; pages:1-10 ; date:12.2024
Blood research ; 59, Heft 1 (28.8.2024), 1-10, 12.2024
- Creator
-
Park, Young-Shil
Yoo, Ki-Young
Park, Sang Kyu
Hwang, Taiju
Jung, Aeran
Choi, Eun Jin
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s44313-024-00023-9
- URN
-
urn:nbn:de:101:1-2411132114319.405038295370
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:25 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Park, Young-Shil
- Yoo, Ki-Young
- Park, Sang Kyu
- Hwang, Taiju
- Jung, Aeran
- Choi, Eun Jin
- SpringerLink (Online service)
Other Objects (12)
Korean version of the MNREAD acuity chart
Pharmacokinetic model-based assessment of factor IX prophylaxis treatment regimens in severe hemophilia B
Real-world experience of emicizumab prophylaxis in Korean children with severe hemophilia A without inhibitors
Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients
Surgery in Hemophilia
Hemophilia in Norway
Chart 1. Chart 2.
Chart 3. Chart 4.
Chart 5. Chart 6.
Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China
Measuring hemophilia caregiver burden: validation of the Hemophilia Caregiver Impact measure
Population Pharmacokinetic Analysis and Exploratory Exposure–Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia A
Korean version of the MNREAD acuity chart
Pharmacokinetic model-based assessment of factor IX prophylaxis treatment regimens in severe hemophilia B
Real-world experience of emicizumab prophylaxis in Korean children with severe hemophilia A without inhibitors
Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients
Surgery in Hemophilia
Hemophilia in Norway
Chart 1. Chart 2.
Chart 3. Chart 4.
Chart 5. Chart 6.
Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China
Measuring hemophilia caregiver burden: validation of the Hemophilia Caregiver Impact measure
Population Pharmacokinetic Analysis and Exploratory Exposure–Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia A
Korean version of the MNREAD acuity chart
Pharmacokinetic model-based assessment of factor IX prophylaxis treatment regimens in severe hemophilia B
Real-world experience of emicizumab prophylaxis in Korean children with severe hemophilia A without inhibitors
Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients
Surgery in Hemophilia
Hemophilia in Norway
Chart 1. Chart 2.
Chart 3. Chart 4.
Chart 5. Chart 6.
Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China
Measuring hemophilia caregiver burden: validation of the Hemophilia Caregiver Impact measure